Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2020.01.27
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
PDF (156 KB)
2020.01.06
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (253 KB)
2019.12.20
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (330 KB)
2019.12.11
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 ...
PDF (220 KB)
2019.11.19
Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with ...
PDF (181 KB)
2019.11.06
Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer P ...
PDF (317 KB)
2019.11.04
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
2019.10.31
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Colla ...
PDF (207 KB)
2019.10.17
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with ...
PDF (171 KB)
2019.09.10
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patie ...
PDF (348 KB)
Showing 1 - 10 of 35 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...